Microcrystalline tableting excipient derived from whey
US4670251A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Sep 20, 1984 |
| Grant date | Jun 2, 1987 |
| Priority date | — |
| Expiry date | Sep 20, 2004 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2063
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A solid pharmaceutical composition suitable for oral or rectal administration comprising a unit dosage of a pharmaceutically active ingredient (and optionally one or more inert fillers) homogeneously dispersed in a pharmaceutically acceptable binder, wherein at least a major portion (i.e., at least 50% by weight) of the binder is a microcrystalline solid phase prepared by raising the pH of a dairy whey lactose permeate having a pH below about 7 to a pH between about 8 and 10 to form (i) a lactose-rich aqueous solute phase capable of being autoclaved for 10-20 minutes at 121.degree. C. and 15 psi to form a clear, light-colored solute having a pH of about 7; and (ii) a microcrystalline solid phase which contains substantially all of the dissolved solids from said solute phase which would form a precipitate upon autoclaving said solid phase; separating the microcrystalline solid phase from the solute phase; and drying the separated microcrystalline solid phase to form a nontoxic, tasteless, odorless, chalky white free-flowing powder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.